ArticleFrontiers in cardiovascular medicine2025
Myocardial infarction with nonobstructive coronary arteries due to acute coronary vasospasm induced by toripalimab: a case report and review of literature.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary artery spasm (CAS), one of the etiologies for MINOCA, is an uncommon cause of acute chest pain. Toripalimab, a recombinant monoclonal antibody targeting programmed death receptor 1 (PD-1), exhibits a wide range of anti-tumor activities. Nevertheless, instances of toripalimab-induced cardiotoxicity have been seldom reported. Methods: We present the case of a 60-year-old male patient diagnosed with hepatocellular carcinoma who experienced MINOCA subsequent to the administration of toripalimab. Based on the patient's symptoms, electrocardiogram (ECG) findings, and coronary angiography, transient occurrence CAS was established. The patient was prescribed diltiazem sustained-release capsules. During his follow-up on an outpatient basis, he did not experience a recurrence of the previously reported chest discomfort or any other symptoms. We used the CARE checklist when writing our report. Conclusion: This is the first case report of MINOCA induced by toripalimab, mediated through coronary artery spasm. This case report emphasizes the awareness regarding the potential for severe cardiovascular complications associated with the administration of toripalimab.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.